NCT00362102View on ClinicalTrials.gov

A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Colorectal Carcinoma
Interventions
DRUG

Cetuximab

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00362102 - A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma | Biotech Hunter | Biotech Hunter